📊 RMTG Key Takeaways
Is Regenerative Medical Technology Group Inc. (RMTG) a Good Investment?
RMTG exhibits severe financial distress with negative stockholders' equity of -$30.1M and a critical liquidity crisis (current ratio 0.09x), indicating technical insolvency. Despite 70.4% revenue growth and healthy 57.6% gross margins, the company generates a -$6.4M net loss on $3.5M revenue with negative operating cash flow of -$744.7K. Without immediate capital restructuring or substantial funding, the company lacks runway to continue operations.
While revenue growth is strong and gross margins are solid, the company remains unprofitable with negative free cash flow and cannot cover interest expenses. Severe liquidity and solvency stress (negative equity and a 0.09x current ratio) create near-term going‑concern risk, likely requiring dilutive financing or restructuring.
Why Buy Regenerative Medical Technology Group Inc. Stock? RMTG Key Strengths
- 70.4% year-over-year revenue growth demonstrates strong market demand
- 57.6% gross margin indicates viable product and pricing power
- Net loss improved 43.3% YoY showing operational trajectory enhancement
- Rapid revenue growth (+70% YoY)
- Strong gross margin (~58%) indicating viable unit economics
- Net loss and EPS improved YoY
RMTG Stock Risks: Regenerative Medical Technology Group Inc. Investment Risks
- Negative stockholders' equity of -$30.1M indicates technical insolvency with liabilities exceeding assets
- Critical liquidity crisis with current ratio 0.09x leaves minimal ability to meet short-term obligations
- Negative operating cash flow of -$744.7K with only $1.2M cash runway insufficient for operational sustainability
- Acute liquidity/solvency stress: negative equity and 0.09x current ratio
- Persistent operating losses and negative FCF; interest coverage -0.2x
- High liabilities vs. assets implying dilution or restructuring risk
Key Metrics to Watch
- Monthly cash burn rate and remaining runway before capital depletion
- Operating expense reduction progress and path to positive cash flow
- Capital raise announcements or debt restructuring events
- Operating cash flow (trend to positive)
- Current ratio (target ≥1.0x)
Regenerative Medical Technology Group Inc. (RMTG) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
RMTG Profit Margin, ROE & Profitability Analysis
RMTG vs Consumer Sector: How Regenerative Medical Technology Group Inc. Compares
How Regenerative Medical Technology Group Inc. compares to Consumer sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Regenerative Medical Technology Group Inc. Stock Overvalued? RMTG Valuation Analysis 2026
Based on fundamental analysis, Regenerative Medical Technology Group Inc. has mixed fundamental signals relative to the Consumer sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Regenerative Medical Technology Group Inc. Balance Sheet: RMTG Debt, Cash & Liquidity
RMTG Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Regenerative Medical Technology Group Inc.'s revenue has grown significantly by 7,357% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.79 indicates the company is currently unprofitable.
RMTG Revenue Growth, EPS Growth & YoY Performance
RMTG Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2024 | $1.6M | -$2.0M | $-0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Regenerative Medical Technology Group Inc. Dividends, Buybacks & Capital Allocation
RMTG SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Regenerative Medical Technology Group Inc. (CIK: 0001760026)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RMTG
What is the AI rating for RMTG?
Regenerative Medical Technology Group Inc. (RMTG) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RMTG's key strengths?
Claude: 70.4% year-over-year revenue growth demonstrates strong market demand. 57.6% gross margin indicates viable product and pricing power. ChatGPT: Rapid revenue growth (+70% YoY). Strong gross margin (~58%) indicating viable unit economics.
What are the risks of investing in RMTG?
Claude: Negative stockholders' equity of -$30.1M indicates technical insolvency with liabilities exceeding assets. Critical liquidity crisis with current ratio 0.09x leaves minimal ability to meet short-term obligations. ChatGPT: Acute liquidity/solvency stress: negative equity and 0.09x current ratio. Persistent operating losses and negative FCF; interest coverage -0.2x.
What is RMTG's revenue and growth?
Regenerative Medical Technology Group Inc. reported revenue of $3.5M.
Does RMTG pay dividends?
Regenerative Medical Technology Group Inc. does not currently pay dividends.
Where can I find RMTG SEC filings?
Official SEC filings for Regenerative Medical Technology Group Inc. (CIK: 0001760026) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RMTG's EPS?
Regenerative Medical Technology Group Inc. has a diluted EPS of $-0.51.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RMTG a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Regenerative Medical Technology Group Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RMTG stock overvalued or undervalued?
Valuation metrics for RMTG: ROE of N/A (sector avg: 18%), net margin of -181.9% (sector avg: 8%). Compare these metrics with sector averages to assess valuation.
Should I buy RMTG stock in 2026?
Our dual AI analysis gives Regenerative Medical Technology Group Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RMTG's free cash flow?
Regenerative Medical Technology Group Inc.'s operating cash flow is $-744.7K, with capital expenditures of $335.4K. FCF margin is -30.6%.
How does RMTG compare to other Consumer stocks?
Vs Consumer sector averages: Net margin -181.9% (avg: 8%), ROE N/A (avg: 18%), current ratio 0.09 (avg: 1.5).